Motor neuron dysfunction in a mouse model of ALS: Gender-dependent effect of P2X7 antagonism

Toxicology

Volumn 311, Issue 1-2, 2013, Pages 69-77

  Cervetto, Chiara ^a   Frattaroli, Daniela ^a   Maura, Guido ^a   Marcoli, Manuela ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Brilliant Blue G; Gender difference; Motor neuron; P2X7 receptor

Indexed keywords

BRILLIANT BLUE; BRILLIANT BLUE G; COPPER ZINC SUPEROXIDE DISMUTASE; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; COORDINATION; DISEASE COURSE; EXPERIMENTAL MODEL; FEMALE; GENE MUTATION; GRIP STRENGTH; LIFESPAN; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; ROTAROD TEST; SEX DIFFERENCE; SURVIVAL; TRANSGENIC MOUSE; WEIGHT REDUCTION;

ALS; AMYOTROPHIC LATERAL SCLEROSIS; BBG; BRILLIANT BLUE G; CU/ZN SUPEROXIDE DISMUTASE 1; D; DAYS OF AGE; GENDER DIFFERENCE; MOTOR NEURON; P2X7 RECEPTOR; SOD1; SOD1/G93A MICE; TRANSGENIC MICE CARRYING A HIGH COPY NUMBER OF A TRANSGENE ENCODING A VARIANT OF HUMAN SUPEROXIDE DISMUTASE 1 WITH A G93A MUTATION (GLY93ALA SUBSTITUTION);

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MOTOR NEURONS; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7; SEX CHARACTERISTICS;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84880772507     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.04.004     Document Type: Article

References (69)

1. Able S.L., Fish R.L., Bye H., Booth L., Logan Y.R., Nathaniel C., Hayter P., Katugampola S.D. Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat. Br. J. Pharmacol. 2011, 162:405-414.
2. Amadio S., Apolloni S., D'Ambrosi N., Volonté C. Purinergic signalling at the plasma membrane: a multipurpose and multidirectional mode to deal with amyotrophic lateral sclerosis and multiple sclerosis. J. Neurochem. 2011, 116:796-805.
3. Arbeloa J., Perez-Samartin A., Gottlieb M., Matute C. P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol. Dis. 2012, 45:954-961.
4. Arnold S., Victor M.B., Beyer C. Estrogen and the regulation of mitochondrial structure and function in the brain. J. Steroid Biochem. Mol. Biol. 2012, 131:2-9.
5. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007, 26:1-13.
6. Bennett M.R., Farnell L., Gibson W.G. P2X7 regenerative-loop potentiation of glutamate synaptic transmission by microglia and astrocytes. J. Theor. Biol. 2009, 261:1-16.
7. Boillée S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
8. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 2007, 87:659-797.
9. Canadian Council on Animal Care, 1998. CCAC guidelines on: choosing an appropriate endpoint in experiments using animals for research, teaching and testing. http://www.ccac.ca/en_/standards/guidelines.
10. Cario-Toumaniantz C., Loirand G., Ferrier L., Pacaud P. Non-genomic inhibition of human P2X7 purinoceptor by 17β-oestradiol. J. Physiol. 1998, 508:659-666.
11. Casanovas A., Hernandez S., Tarabal O., Rossello J., Esquerda J. Strong P2X4 purinergic receptor-like immunoreactivity is selectively associated with degenerating neurone in transgenic rodent models of Amyotrophic Lateral Sclerosis. J. Comp. Neurol. 2008, 506:75-92.
12. Cervetto C., Mazzotta M.C., Frattaroli D., Alloisio S., Nobile M., Maura G., Marcoli M. Calmidazolium selectively inhibits exocytotic glutamate release evoked by P2X7 receptor activation. Neurochem. Int. 2012, 60:768-772.
13. Cervetto C., Alloisio S., Frattaroli D., Mazzotta M.C., Milanese M., Gavazzo P., Passalacqua M., Nobile M., Maura G., Marcoli M. The P2X7 receptor as a route for non-exocytotic glutamate release: dependence on the carboxyl tail. J. Neurochem. 2013, 7. 10.1111/jnc.12143.
14. D'Ambrosi N., Finocchi P., Apolloni S., Cozzolino M., Ferri A., Padovano V., Pietrini G., Carri{dotless}' M.T., Volonte C. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J. Immunol. 2009, 183:4648-4656.
15. Deshpande S.B., Pilotte N.S., Warnick J.E. Gender-specific action of thyrotropin-releasing hormone in the mammalian spinal cord. FASEB J. 1987, 1:478-482.
16. Díaz-Amarilla P., Olivera-Bravo S., Trias E., Cragnolini A., Martínez-Palma L., Cassina P., Beckman J., Barbeito L. Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:18126-18131.
17. Díaz-Hernández M., Díez-Zaera M., Sánchez-Nogueiro J., Gómez-Villafuertes R., Canals J.M., Alberch J., Miras-Portugal M.T., Lucas J.J. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J. 2009, 23:1893-1906.
18. Díaz-Hernández J.I., Gómez-Villafuertes R., León-Otegui M., Hontecillas-Prieto L., del Puerto A., Trejo J.L., Lucas J.J., Garrido J.J., Gualix J., Miras-Portugal M.T., Díaz-Hernández M. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3 and secretases. Neurobiol. Aging 2012, 33:1816-1828.
19. Duan S., Neary J.T. P2X7 receptors: properties and relevance to CNS function. Glia 2006, 54:738-746.
20. Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M.L., Lazzeri G., Spalloni A., Bellio N., Lenzi P., Modugno N., Siciliano G., Isidoro C., Murri L., Ruggirei S., Paparelli A. Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2052-2057.
21. 7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J. Neuroinflammat. 2010, 7:33. 10.1186/1742-2094-7-33.
22. Genestine M., Caricati E., Fico A., Richelme S., Hassani H., Sunyach C., Lamballe F., Panzica G.C., Pettmann B., Helmbacher F., Raoul C., Maina F., Dono R. Enhanced neuronal Met signalling levels in ALS mice delay disease onset. Cell Death Dis. 2011, 2:e130. 10.1038/cddis.2011.11.
23. Gillies G.E., McArthur S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol. Rev. 2010, 62:155-198.
24. Gorodeski G.I. Estrogen attenuates P2X7-R-mediated apoptosis of uterine cervical cells by blocking calcium influx. Nucleosides Nucleotides Nucleic Acids 2004, 23:1287-1293.
25. Groeneveld G.J., Van Muiswinkel F.L., Sturkenboom J.M., Wokke J.H., Bar P.R., Van den Berg L.H. Ovariectomy and 17beta-estradiol modulate disease progression of a mouse model of ALS. Brain Res. 2004, 1021:128-131.
26. Grygorowicz T., Struzyńska L., Sulkowski G., Chalimoniuk M., Sulejczak D. Temporal expression of P2X7 purinergic receptor during the course of experimental autoimmune encephalomyelitis. Neurochem. Int. 2010, 57:823-829.
27. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
28. Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., Hall E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 1996, 39:147-157.
29. Hamilton N., Vayro S., Kirchhoff F., Verkhratsky A., Robbins J., Gorecki D.C., Butt A.M. Mechanisms of ATP- and glutamate-mediated calcium signaling in white matter astrocytes. Glia 2008, 56:734-749.
30. Hayworth C.R., Gonzalez-Lima F. Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model. Neuroscience 2009, 164:975-985.
31. Heiman-Patterson T.D., Deitch J.S., Blankenhorn E.P., Erwin K.L., Perreault M.J., Alexander B.K., Byers N., Toman I., Alexander G.M. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 2005, 236:1-7.
32. Hensley K., Mhatre M., Mou S., Pye Q.N., Stewart C., West M., Williamson K.S. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid. Redox Signal. 2006, 8:2075-2087.
33. Iwamaru Y., Takenouchi T., Murayama Y., Okada H., Imamura M., Shimizu Y., Hashimoto M., Mohri S., Yokoyama T., Kitani H. Anti-prion activity of Brilliant Blue G. PLoS ONE 2012, 7(5):e37896. 10.1371/journal.pone.0037896.
34. Jiang L.H., Mackenzie A.B., North R.A., Surprenant A. Brilliant Blue G selectively blocks ATP-gated rat P2X7 receptors. Mol. Pharmacol. 2000, 58:82-88.
35. Jo S., Bean B.P. Inhibition of neuronal voltage-gated sodium channels by brilliant blue G. Mol. Pharmacol. 2011, 80:247-257.
36. Ke H.Z., Qi H., Weidema A.F., Zhang Q., Panupinthu N., Crawford D.T., Grasser W.A., Paralkar V.M., Li M., Audoly L.P., Gabel C.A., Jee W.S., Dixon S.J., Sims S.M., Thompson D.D. Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol. Endocrinol. 2003, 17:1356-1367.
37. Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet 2011, 377:942-955.
38. Knippenberg S., Thau N., Dengler R., Petri S. Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS). Behav. Brain Res. 2010, 213:82-87.
39. Lewis C.-A., Manning J., Rossi F., Krieger C. The neuroinflammatory response in ALS: the roles of microglia and T cells. Neurol. Res. Int. 2012, 2012:803701. 10.1155/2012/803701.
40. Ludolph A.C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J.P., Mead R., Niessen H.G., Petri S., Pradat P.F., Robberecht W., Ruegg M., Schwalenstöcker B., Stiller D., van den Berg L., Vieira F., von Horsten S. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph. Lateral Scler. 2010, 11:38-45.
41. Marcoli M., Cervetto C., Paluzzi P., Guarnieri S., Alloisio S., Thellung S., Nobile M., Maura G. P2X7 presynaptic receptors in adult rat cerebrocortical nerve terminals: a role in ATP-induced glutamate release. J. Neurochem. 2008, 105:2330-2342.
42. Matute C., Torre I., Pérez-Cerdá F., Pérez-Samartín A., Alberdi E., Etxebarria E., Arranz A.M., Ravid R., Rodríguez-Antigüedad A., Sánchez-Gómez M.V., Domercq M. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J. Neurosci. 2007, 27:9525-9533.
43. McCombe P.A., Henderson R.D. Effects of gender in amyotrophic lateral sclerosis. Gend. Med. 2010, 7:557-570.
44. McLarnon J.G., Ryu J.K., Walker D.G., Choi H.B. Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptidetreated microglia and in peptide-injected rat hippocampus. J. Neuropathol. Exp. Neurol. 2006, 65:1090-1097.
45. Milanese M., Zappettini S., Bacchetti E., Bonifacino T., Cervetto C., Usai C., Bonanno G. In vitro activation of GAT1 transporters expressed in spinal cord gliosomes stimulates glutamate release that is abnormally elevated in the SOD1/G93A(+) mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2010, 113:489-501.
46. Miquel E., Cassina A., Martínez-Palma L., Bolatto C., Trías E., Gandelman M., Radi R., Barbeito L., Cassina P. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS ONE 2012, 7(4):e34776. 10.1371/journal.pone.0034776.
47. Mosley R.L., Gendelman H.E. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Exp. Neurol. 2010, 222:1-5.
48. Naumenko N., Pollari E., Kurronen A., Giniatullina R., Shakirzyanova A., Magga J., Koistinaho J., Giniatullin R. Gender-specific mechanism of synaptic impairment and its prevention by GCSF in a mouse model of ALS. Front. Cell. Neurosci. 2011, 5:26. 10.3389/fncel.2011.00026.
49. Nefussy B., Drory V.E. Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies. EPMA J. 2010, 1:329-341.
50. North R.A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82:1013-1067.
51. Novak I., Jans I.M., Wohlfahrt L. Effect of P2X7 receptor knockout on exocrine secretion of pancreas, salivary glands and lacrimal glands. J. Physiol. 2010, 588:3615-3627.
52. Parvathenani L.K., Tertyshnikova S., Greco C.R., Roberts S.B., Robertson B., Posmantur R. P2X7 mediates superoxide production in primary microglia and is upregulated in a transgenic mouse model of Alzheimer's disease. J. Biol. Chem. 2003, 278:13309-13317.
53. Peng W., Cotrina M.L., Han X., Yu H., Bekar L., Blum L., Takano T., Tian G.-F., Goldman S.A., Nedergaard M. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12489-12493.
54. Philips T., Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011, 10:253-263.
55. Pieri M., Carunchio I., Curcio L., Mercuri N.B., Zona C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp. Neurol. 2009, 215:368-379.
56. Ryu J.K., McLarnon J.G. Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer's disease. Neuroreport 2008, 19:1715-1719.
57. Schäfera S., Hermans E. Reassessment of motor-behavioural test analyses enables the detection of early disease-onset in a transgenic mouse model of amyotrophic lateral sclerosis. Behav. Brain Res. 2011, 225:7-14.
58. Solomon J.A., Tarnopolsky M.A., Hamadeh M.J. One universal common endpoint in mouse models of amyotrophic lateral sclerosis. PLoS ONE 2011, 6(6):e20582. 10.1371/journal.pone.0020582.
59. Sperlagh B., Vizi E.S., Wirkner K., Illes P. P2X7 receptors in the nervous system. Prog. Neurobiol. 2006, 78:327-346.
60. Takenouchi T., Sekiyama K., Sekigawa A., Fujita M., Waragai M., Sugama S., Iwamaru Y., Kitani H., Hashimoto M. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch. Immunol. Ther. Exp. (Warsz) 2010, 58:91-96.
61. Trieu V.N., Uckun F.M. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem. Biophys. Res. Commun. 1999, 258:685-688.
62. Uccelli A., Milanese M., Principato M.C., Morando S., Bonifacino T., Vergani L., Giunti D., Voci A., Carminati E., Giribaldi F., Caponnetto C., Bonanno G. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol. Med. 2012, 18:794-804.
63. Veldink J.H., Bar P.R., Joosten E.A., Otten M., Wokke J.H., van den Berg L.H. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul. Disord. 2003, 13:737-743.
64. Verkhrasky A., Krishtal O.A., Burnstock G. Purinoceptors on neuroglia. Mol. Neurobiol. 2009, 39:190-208.
65. Wang X., Arcuino G., Takano T., Lin J., Peng W.G., Wan P., Li P., Xu Q., Liu Q.S., Goldman S.A., Nedergaard M. P2X7 receptor inhibition improves recovery after spinal cord injury. Nat. Med. 2004, 10:821-827.
66. Wang Q., Li X., Wang L., Feng Y.-H., Zeng R., Gorodeski G. Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells. Endocrinology 2004, 145:5568-5579.
67. Weydt P., Hong S.Y., Kliot M., Moller T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport 2003, 14:1051-1054.
68. Yiangou Y., Facer P., Durrenberger P., Chessell I.P., Naylor A., Bountra C., Banati R.R., Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006, 2:6-12.
69. Zinman L., Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 2011, 10:481-490.